The global acute repetitive seizures market is expected to grow at a CAGR of about 46.7% over the forecast period and to reach valuation US$ 4.3 billion by 2027.
The global acute repetitive seizures market is expected to grow at a CAGR of about 46.7% over the forecast period and to reach valuation US$ 4.3 billion by 2027.
The rising investments in the research and development, increasing number of clinical trials, rising investments towards the development of new and innovative therapies, and new product launches are some of the major factors that drives the growth of the global acute repetitive seizures market. Furthermore, an increase in the number approvals and a number of promising drugs in the pipeline are expected to augment the market growth. The rising popularity of the nasal sprays for the treatment of epilepsy is positively impacting the market growth across the globe.
Get the sample copy of report@ https://www.precedenceresearch.com/sample/1164
The rising concerns regarding the increasing healthcare costs has resulted in the increased government initiatives to promote the outpatient model and thus the rapid growth of the clinics and home healthcare is expected to drive the growth of the acute repetitive seizures market. The rising incidents of epilepsy is significantly boosting the market growth. It is estimated that around 3.4 million people in US are suffering from epilepsy. The surging unmet demands for the patients and the caretakers is expected to spur the demand for the acute repetitive seizures.
Report Highlights:
- Depending on the product, the diastat rectal gel segment dominated the global acute repetitive seizures market in 2019. This is attributed to the lack of the government approval of the drugs available in the market and the high efficiency of the diastat rectal gel. The diastat rectal gel is the only approved product in the market that has led to the dominance of this segment.
- The NRL-1 is projected to grow at the highest CAGR during the forecast period. This drug is developed by the Neurelis for use on the adults, children, and adolescents.
- North America was the dominant acute repetitive seizures market in 2019. The rising prevalence of neurological disorders and brain injuries, surging number of drug approvals, and the availability of strong healthcare infrastructure in the region are the prominent drivers of the North America acute repetitive seizures market. According to the National Center for Biotechnology Information, each year 50,000 to 150,000 individuals in the U.S. were affected with status epilepticus.The mortality in kids was projected at less than 3%, and around 30% in adults. The presence of major market players in the region and their increasing investments in the research and new product development has significantly contributed towards the growth of the North America acute repetitive seizures market.
- Asia Pacific is projected to grow at a rapid rate in the upcoming future. The growth is attributed to the presence of higher number epilepsy population, surging awareness regarding epilepsy, growing prevalence of neurological disorders, rapidly growing geriatric population, and growing emphasis on the development of advanced healthcare infrastructure in the region are some of the major factors that are expected to drive the growth of the acute repetitive seizures market.
Ask here for customization@ https://www.precedenceresearch.com/customization/1164
Future of Acute Repetitive Seizures Market
The global acute repetitive seizures market is expected to witness a rapid surge in the investments towards the clinical trials and acquiring approvals. The government authorities like FDA will play a crucial role in the growth of the market in the upcoming future.
COVID-19 Impact Analysis
- The spread of COVID-19 in the start of 2020 has disrupted the operation of several industries including healthcare sector as well
- During COVID-19, the focus of the government bodies along with the reputed companies had shifted towards the study of the COVID-19 virus, their features and cure that hampered the research on acute repetitive seizures
- Further, country lockdown and social distancing norms have significantly impacted the industry operations
Key Developments in the Marketplace:
- In January 2020, Neurelis, stated that the U.S. FDA has legalized diazepam nasal spray named VALTOCO as an acute treatment of intermittent, stereotypic episodes of recurrent seizure movement that are dissimilar from a patient’s general seizure pattern in persons with epilepsy 6 years of age and older. The exclusive formulation of VALTOCO includes Intravail for reliable and consistent absorption.
- In May 2019, UCB declared that the U.S. FDA has permitted a New Drug Application for the company’s latest anti-epileptic drug (AED) NAYZILAM nasal spray CIV. It is a benzodiazepine designated for the stereotypic incidents of recurrent seizure activity and acute treatment of intermittent that are different from a patient’s normal seizure form in person with epilepsy 12 years and older1. NAYZILAM delivers caregivers and patients with the foremost and only FDA-approved nasal selection for treating seizure clusters.
Market Segmentation
Product Outlook
- NRL-1
- Diastat Rectal Gel
- USL-261
- AZ-002
- Others
Regional Outlook
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa (MEA)
Click Here to View Full Report Table of Contents
Buy this Research Report@ https://www.precedenceresearch.com/checkout/1164
You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 9197 992 333